The probability of being cost-effective at a $100,000 per QALY threshold was 64% for tirzepatide and 34% for semaglutide. HealthDay News — Compared with usual care, the glucagon-like peptide 1 ...
Reflecting longstanding concerns about potentially discriminatory methodologies, Congress has resisted reliance on quality-adjusted life-years (QALYs) as a determining factor for health care decisions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results